Related Experiment Video
Updated: Jul 18, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model
Jesse A Stoff1, David E Nix, D W DeYoung
1Tiburon Laboratory, Tucson, Arizona 85745, USA. thedoc@drstoff.com
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules. It was evaluated in vivo using a mouse model of MRSA-induced peritonitis. Intraperitoneal dosing of anti-MRSA BLC demonstrated a therapeutic effect (83% survival) against an intraperitoneal MRSA challenge that caused 100% mortality in untreated animals. Anti-MRSA BLC is a promising therapeutic modality for MRSA infection.
Insights
A novel bioengineered lacteal complex (BLC) shows promise for treating Methicillin-resistant Staphylococcus aureus (MRSA) infections. In a mouse model, anti-MRSA BLC significantly improved survival rates against a lethal MRSA challenge.
Area of Science:
- Microbiology
- Immunology
- Biotechnology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen in human and animal health.
- MRSA infections can lead to severe conditions like septicemia, abscesses, and toxemia.
Purpose of the Study:
- To evaluate the therapeutic efficacy of a novel bioengineered lacteal complex (BLC) against MRSA.
- To assess the in vivo effectiveness of anti-MRSA BLC in a relevant animal model.
Main Methods:
- A mouse model of MRSA-induced peritonitis was utilized.
- Intraperitoneal administration of anti-MRSA BLC was performed.
- Survival rates in treated and untreated groups were compared.
Main Results:
- Intraperitoneal dosing of anti-MRSA BLC resulted in an 83% survival rate.
- Untreated control animals experienced 100% mortality from the MRSA challenge.
- The bioengineered lacteal complex demonstrated a significant therapeutic effect.
Conclusions:
- Anti-MRSA BLC is a promising novel therapeutic agent for MRSA infections.
- The low molecular weight immunogenic and antimicrobial properties of BLC contribute to its efficacy.
- Further development of BLC could offer a new treatment option for challenging MRSA infections.
